Mexiletine and quinidine in ventricular ectopy

Area of Science:

• Cardiology
• Pharmacology

Background:

• Chronic ventricular ectopy poses a significant risk for cardiac events.
• Assessing the comparative efficacy of antiarrhythmic drugs is crucial for patient management.

Purpose of the Study:

• To compare the antidysrhythmic efficacy and tolerance of mexiletine and quinidine.
• To evaluate the effectiveness of these drugs in reducing ventricular ectopic frequency.

Main Methods:

• A double-blind, dose-ranging study was conducted on 26 ambulatory patients with chronic ventricular ectopy.
• Patients were randomized to receive either mexiletine or quinidine.
• Efficacy was assessed by comparing 24-hour ambulatory ECG recordings before and after treatment, defining success as a ≥70% reduction in ventricular ectopic frequency.

Main Results:

• Both mexiletine and quinidine achieved at least a 70% reduction in ventricular ectopic frequency in a substantial proportion of patients (7/13 for mexiletine, 8/13 for quinidine).
• Neither drug consistently abolished complex forms of ventricular ectopy.
• The incidence and severity of adverse effects were comparable between the two treatment groups.

Conclusions:

• Mexiletine is as effective as quinidine in suppressing chronic ventricular ectopy.
• Adverse effects limit the use of both mexiletine and quinidine in managing ventricular ectopy.